Clinical Trial

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Study acronym: TBI-1501
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2017-05-15; most recent amendment 2024-11-18.
Status change: Recruiting → Active, Not Recruiting 2022-06-15
Status change: Not Yet Recruiting → Recruiting 2017-06-11
Trial Details
NCT Number NCT03155191
Lead Sponsor Takara Bio Inc.
Conditions Lymphoblastic Leukemia, Acute Adult
Enrollment 21 participants
Start Date 2017-06-01
Primary Completion 2035-03-31 (estimated)
Study Completion 2035-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-20